Evidence map›Paper›PMID 40116278›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Targeted DNA Nanomachine Enables Specific miRNA-Responsive Singlet Oxygen Amplification for Precise Cutaneous Squamous Cancer Therapy.

Hanane Aliouat, Detian Zhang, Lanyuan Peng, Jiaxin Huang, Hongshi Cheng, Jiaojiao Zhu, Xiang Chen, Nuli Xie, Wenhu Zhou, Shuang Zhao

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hanane AliouatXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China.
Detian ZhangDepartment of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Lanyuan PengDepartment of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jiaxin HuangXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China.
Hongshi ChengXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China.
Jiaojiao ZhuXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China.
Xiang ChenDepartment of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Nuli XieXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China.ORCID https://orcid.org/0000-0002-8846-0532
Wenhu ZhouXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China.
Shuang ZhaoDepartment of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.

Funding

Furong Laboratory Research Project of Hunan Province 2024PT5110National Natural Science Foundation of China 22404178Natural Science Foundation of Hunan Province 2023JJ40711
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a promising strategy for the treatment of skin-related tumors including cutaneous squamous cells carcinoma (cSCC). However, it is hard to balance the dosage off-target phototoxicity while maintaining satisfactory therapeutic effect. In addition, oxygen-dependent photosensitizers (PSs) are affected by tumor hypoxic environment, which further causes inefficient photocatalysis and reduces therapeutic effect. Herein, an intelligent DNA nanomachine based on tetrahedral DNA framework is proposed, incorporated with tumor-targeted aptamer and specific miRNA-responsive hairpin DNA catalytic assembly (HCA), for precise and high-efficient therapy of cSCC. After aptamer-mediated targeted delivery, a cSCC-specific miRNA selected by tissue sequencing analysis is used to activateHCA, for amplifying PSs and controllably releasing chemotherapeutic drugs. Sequential recognition can greatly improve tumor-specific accumulation and high-dose activation. Moreover, hemin is incorporated into DNA to catalytically produce oxygen. In vitro and in vivo experiments demonstrated that this DNA nanomachine greatly improved anti-tumor effect and realized effective ablation of cSCC in mice, with barely systemic toxicity and inflammation. It is anticipated that this strategy will promote biomedical applications of tumor-specific miRNA and provide a promising option for the non-invasive treatment of skin-associated tumors.

Indexed as

Carcinoma, Squamous CellDNAMicroRNAsPhotochemotherapySinglet OxygenSkin NeoplasmsAnimalsCell Line, TumorHumansMicePhotosensitizing AgentsDNAMicroRNAsPhotosensitizing AgentsSinglet OxygenDNA nanotechnologyDNA tetrahedramicroRNAphotodynamic therapyskin tumors

Identifiers

PMID40116278
PMCPMC12097105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.